Debt to Equity Ratio Chart

View Debt to Equity Ratio for CPH.TO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 0.0027
March 31, 2026 0.0032
December 31, 2025 0.0436
September 30, 2025 0.1175
June 30, 2025 0.2326
March 31, 2025 0.3849
December 31, 2024 0.3965
September 30, 2024 0.4122
June 30, 2024 0.0033
March 31, 2024 0.0038
December 31, 2023 0.0044
September 30, 2023 0.0046
June 30, 2023 0.0055
March 31, 2023 0.006
December 31, 2022 0.0067
September 30, 2022 0.01
June 30, 2022 0.0121
March 31, 2022 0.013
December 31, 2021 0.0133
September 30, 2021 0.00
June 30, 2021 0.0516
March 31, 2021 0.0543
December 31, 2020 0.0566
September 30, 2020 0.1055
June 30, 2020 0.1745
Date Value
March 31, 2020 0.2408
December 31, 2019 0.3416
September 30, 2019 0.5112
June 30, 2019 0.6234
March 31, 2019 0.7317
December 31, 2018 0.7182
September 30, 2018 0.7595
June 30, 2018 0.8703
March 31, 2018 0.74
December 31, 2017 0.7826
September 30, 2017 1.036
June 30, 2017 1.219
March 31, 2017 2.598
December 31, 2016 2.027
September 30, 2016 1.224
June 30, 2016 0.7022
March 31, 2016 0.6635
December 31, 2015 0.6373
September 30, 2015 0.6662
June 30, 2015 0.64
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.00

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
HLS Therapeutics, Inc. 0.7586
Bausch Health Cos., Inc. -11.73
BioSyent, Inc. 0.0685
Revive Therapeutics Ltd. -0.0176
Knight Therapeutics, Inc. 0.0429